Affiliation:
1. Post-Graduate Program in Biochemistry and Molecular Biology, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil
2. Center for Technology and Natural Resources, Federal University of Campina Grande, Campina Grande 58429-900, Brazil
3. Graduate Program in Food Engineering, Federal University of Campina Grande, Campina Grande 58429-900, Brazil
Abstract
This review article covers the therapeutic potential of the plants Harpagophytum procumbens and Turnera subulata in the treatment of neurodegenerative diseases. Despite the recognition of their beneficial properties, there is notable shortage of specific clinical and in vitro studies on these species regarding neurodegenerative diseases. Compounds such as harpagosides and vite-xin-2-O-rhamnoside, found in Harpagophytum procumbens and Turnera subulata, respectively, as well as other antioxidants and anti-inflammatory agents, are associated with mechanisms of action that involve reducing oxidative stress and modulating the inflammatory response, indicating their therapeutic potential in these pathologies. Additionally, the use of nutraceuticals derived from medicinal plants has emerged as a promising approach, offering natural therapeutic alternatives. However, the pressing need for studies focusing on the pharmacokinetics, safety, and pharmacological interactions of these extracts for the treatment of neurodegenerative diseases is emphasized. This review also evaluated advances in nutraceutical delivery systems, highlighting technological innovations that can optimize the precise delivery of these compounds to patients. Such findings highlight the gaps in the study of these plants for the treatment of neurodegenerative diseases and, at the same time, the potential for opening new perspectives in the treatment of neurodegenerative diseases, providing expectations for innovative solutions in this critical domain of medicine.
Funder
CNPq
FAPESQ
University of Campina Grande—UFCG/CAPES-PROAP
Reference120 articles.
1. Recent Progress and Challenges in the Application of Molecularly Imprinted Polymers for Early-Stage Screening of Neurodegenerative Diseases-Related Protein Biomarkers;Adampourezare;Microchem. J.,2023
2. Epstein Barr Virus Nuclear Antigen 1 (EBNA-1) Peptides Recognized by Adult Multiple Sclerosis Patient Sera Induce Neurologic Symptoms in a Murine Model;Jog;J. Autoimmun.,2020
3. Neurodegeneration in Multiple Sclerosis Involves Multiple Pathogenic Mechanisms;Levin;Degener. Neurol. Neuromuscul. Dis.,2014
4. Guggulsterone Ameliorates Ethidium Bromide-Induced Experimental Model of Multiple Sclerosis via Restoration of Behavioral, Molecular, Neurochemical and Morphological Alterations in Rat Brain;Kumar;Metab. Brain Dis.,2021
5. Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region;Hittle;JAMA Neurol.,2023